查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571747

製藥 CRO 市場規模、佔有率和趨勢分析報告：按類型、分子類型、服務、治療領域、地區和細分市場進行預測，2024-2030 年

Pharmaceutical CRO Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical), By Molecule Type (Small Molecules, Large Molecules), By Services, By Therapeutic Areas, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

製藥 CRO 市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球醫藥CRO市場規模預計將達到629.9億美元。

由於外包趨勢的上升和研發費用的上升，預計市場在預測期內將呈現 7.32% 的複合年成長率。

製藥 CRO 以合約形式向各製藥公司提供外包服務。製藥公司外包的增加、新藥研發投資的增加、製藥業的擴張以及幫助 CRO 減少營運和資本支出是預計在預測期內推動市場成長的主要因素之一。

此外，對 CRO 需求的成長歸因於對藥物開發、產品維護和相關服務改進的需求不斷成長，預計這將推動未來幾年的市場成長。此外，主要市場參與者的存在和全球正在進行的臨床試驗預計將推動市場成長。例如，根據美國國家醫學圖書館的數據，目前全球約有 83,230 項臨床試驗正在開放和招募中。同樣，藥物開發活動的增加、技術創新和收購等策略性舉措、製藥公司的存在不斷增加以及對製藥 CRO 創新服務的需求激增是推動市場成長的主要因素。

此外，擴大與新藥開發相關的技術創新以及增加生技藥品的研發預計將對市場產生正面影響。目前，製藥公司擴大獲得 CRO 提供的新的高度專業化的專業知識和技術，以進行各種小分子和大分子的創新。此外，由於 CRO 支持早期檢測和臨床前測試，大多數製藥 CRO 對小分子候選藥物的開發有很高的需求。例如，2023年3月，Crown Biosciences & JSR Lifesciences宣佈在新加坡設立新基地。該中心將為參與臨床前和轉化腫瘤藥物發現和開發的公司提供支援。

製藥 CRO 市場報告亮點

  • 由於藥物開發場景的變化以及需要先進的能力來支持製藥公司推進藥品製造，臨床部門在 2023 年以 75.85% 的銷售佔有率佔據市場主導地位。此外，成本效益和 CRO 數量的增加對市場成長有正面影響。
  • 由於標靶治療潛力不斷成長、個人化醫療需求不斷增加以及製藥公司對小分子的興趣增加，小分子領域將在 2023 年佔據市場主導地位。此外，小分子藥物管道的擴張預計將為CRO提供服務創造機會。
  • 按服務分類，臨床監測佔最大市場佔有率，2023年為20.15%。這是由於擴大採用臨床試驗管理，其中包括監管要求的監控以及從方案開拓到資料分析的一切，使其成為廣泛臨床試驗的可行選擇。
  • 以治療領域來看，腫瘤治療佔最大市場佔有率，2023年將達30.46%。該行業受到癌症發病率上升、人口老化和對藥品的強勁需求的推動，從而使其在該行業佔據主導地位。
  • 亞太地區在2023年佔據全球市場的主導地位，銷售額佔有率為45.60%。該地區的高市場佔有率歸因於活躍在中國和日本等國家的 CRO 的增加。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 製藥 CRO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望。
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 醫藥CRO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章醫藥CRO市場：類型估計與趨勢分析

  • 細分儀表板
  • 全球醫藥CRO市場類型波動分析
  • 2018-2030年全球製藥CRO市場規模及趨勢分析（按類型）
  • 藥物發現
  • 臨床前
  • 臨床

第5章 醫藥CRO市場：分子類型估算及趨勢分析

  • 細分儀表板
  • 全球醫藥CRO市場分子類型波動分析
  • 2018-2030年全球製藥CRO市場規模及趨勢分析（依分子型態）
  • 低分子
  • 大分子

第6章醫藥CRO市場：服務評估與趨勢分析

  • 細分儀表板
  • 全球醫藥CRO市場服務波動分析
  • 2018年至2030年全球製藥CRO市場規模及趨勢分析（依服務）
  • 計劃管理/臨床供應管理
  • 資料管理
  • 監管/醫療
  • 醫學寫作
  • 臨床監測
  • 品管/保證
  • 生物統計學
  • 支付給調查員
  • 實驗室
  • 病人和設施招募
  • 科技
  • 其他

第7章 醫藥CRO市場：治療領域預估及趨勢分析

  • 細分儀表板
  • 全球醫藥CRO市場治療領域波動分析
  • 2018年至2030年全球製藥CRO市場規模及趨勢分析（依治療領域）
  • 腫瘤學
  • 中樞神經系統疾病
  • 感染疾病
  • 免疫疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 糖尿病
  • 眼科
  • 疼痛管理
  • 其他

第8章醫藥CRO市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 2018-2030年北美市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 2018-2030 年亞太市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018年至2030年中東和非洲市場估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 公司/競爭對手分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/上市公司
    • Parexel International（MA）Corporation.
    • ICON plc
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Inc.
    • Medpace
    • IQVIA
    • CTI Clinical Trial &Consulting
    • WuXi AppTec
    • Veeda Clinical Research
Product Code: GVR-4-68040-470-0

Pharmaceutical CRO Market Growth & Trends:

The global pharmaceutical CRO market size is expected to reach USD 62.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to show a lucrative CAGR of 7.32% over the forecast period due to rising outsourcing trends and increasing R&D expenditure.

Pharmaceutical CROs provide outsourcing services to various pharmaceutical companies on a contract basis. Increasing outsourcing among pharmaceutical companies, growing investments in the R&D of new drugs, expansions in the pharmaceutical industry, and CRO support in reducing operational and capital expenses are some of the major factors anticipated to propel market growth in the forecast period.

Besides, increasing demand for CRO is driven by rising requirements for improved drug development, product maintenance, and related services, which is expected to drive market growth in the coming years. In addition, the substantial presence of key market players and ongoing clinical trials globally are expected to drive market growth. For instance, according to the U.S. National Library of Medicine, about 83,230 clinical trial studies are currently active and recruiting globally, which is anticipated to contribute to market growth. Likewise, increasing drug development activities, strategic initiatives such as innovation & acquisitions, the growing presence of pharmaceutical companies, and a surge in demand for pharmaceutical CRO innovative services are key factors propelling the market growth.

Furthermore, growing technological innovations pertaining to developing novel pharmaceutical drugs and rising research and development for biologics are anticipated to influence the market positively. Currently, pharmaceutical companies are increasingly bolstering their capacities in CRO's newer, highly specific expertise and technologies for the innovation of various small & large molecules. In addition, most pharmaceutical CROs have an emerging demand for small molecule drug candidates' development as CRO supports early discovery and preclinical drug development studies. For instance, in March 2023, Crown Bioscience & JSR Life Sciences Company mentioned it's a new site in Singapore, which will support the company in expanding its capacity for biotech & pharma companies. The site will help companies that engage in preclinical & translational oncology drug discovery and development.

Pharmaceutical CRO Market Report Highlights:

  • The clinical segment dominated the market with a revenue share of 75.85% in 2023 due to changing drug development scenarios and the need for sophisticated capabilities to help pharmaceutical companies advance drug manufacturing. In addition, cost-effectiveness and the increasing number of CROs are some of the key factors positively affecting market growth.
  • The small molecules segment dominated the market in 2023 owing to the increasing potential of targeted therapies, rising demand for personalized medicine, and pharmaceutical companies' growing interest in small molecules. Besides, the expanding pipeline of small molecule drugs is anticipated to create opportunities for CROs to provide services.
  • Based on service, clinical monitoring held the largest market share of 20.15% in 2023, which is attributed to the increase in the adoption of monitoring of regulatory requirements and clinical trial management, which includes protocol development to data analysis, making it a suitable option for a wide range of clinical trials.
  • In terms of therapeutic areas, the oncology segment held the largest market share of 30.46% in 2023. The segment is driven by the growing incidence of cancer, the rising aging population, and the robust demand for pharmaceuticals, contributing to its prominence in this field.
  • Asia Pacific dominated the market globally with a revenue share of 45.60% in 2023. The region's high share is due to an increased number of actively functioning CROs, especially in China and Japan, among others.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Molecule Type Segment
    • 1.2.3. Services Segment
    • 1.2.4. Therapeutic Areas Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand For Outsourcing Services
      • 3.2.1.2. Increasing Adoption of Advanced Technologies
      • 3.2.1.3. Increasing Mergers and Collaborations
      • 3.2.1.4. Increasing Demand for Outsourcing Services Across The Developing Economies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk Associated with Data Security
      • 3.2.2.2. Monitoring Issues and Lack of Standardization
  • 3.3. Pharmaceutical CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical CRO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pharmaceutical CRO Market Type Movement Analysis
  • 4.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Drug Discovery
    • 4.4.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Target Validation
      • 4.4.2.1. Target validation market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Lead Identification
      • 4.4.3.1. Lead identification market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Lead Optimization
      • 4.4.4.1. Lead optimization market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Pre-Clinical
    • 4.5.1. Pre-Clinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Clinical
    • 4.6.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.2. Phase I Trial Services
      • 4.6.2.1. Phase I Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.3. Phase II Trial Services
      • 4.6.3.1. Phase II Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.4. Phase III Trial Services
      • 4.6.4.1. Phase III Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.5. Phase IV Trial Services
      • 4.6.5.1. Phase IV Trial Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical CRO Market: Molecule Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical CRO Market Molecule Type Movement Analysis
  • 5.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Large Molecules
    • 5.5.1. Large Molecules market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical CRO Market: Services Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical CRO Market Services Movement Analysis
  • 6.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
  • 6.4. Project Management/Clinical Supply Management
    • 6.4.1. Project Management/Clinical Supply Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Data Management
    • 6.5.1. Data Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Regulatory/Medical Affairs
    • 6.6.1. Regulatory/Medical Affairs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Medical Writing
    • 6.7.1. Medical Writing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Clinical Monitoring
    • 6.8.1. Clinical Monitoring market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Quality Management/ Assurance
    • 6.9.1. Quality Management/ Assurance market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Biostatistics
    • 6.10.1. Bio-statistics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Investigator Payments
    • 6.11.1. Investigator Payments market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Laboratory
    • 6.12.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.13. Patient And Site Recruitment
    • 6.13.1. Patient And Site Recruitment market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.14. Technology
    • 6.14.1. Technology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.15. Others
    • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical CRO Market: Therapeutic Areas Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical CRO Market Therapeutic Areas Movement Analysis
  • 7.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. CNS Disorders
    • 7.5.1. CNS Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Infectious Diseases
    • 7.6.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Immunological Disorders
    • 7.7.1. Immunological Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Cardiovascular Disease
    • 7.8.1. Cardiovascular Disease market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Respiratory Diseases
    • 7.9.1. Respiratory Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Diabetes
    • 7.10.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.11. Ophthalmology
    • 7.11.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.12. Pain Management
    • 7.12.1. Pain Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.13. Other
    • 7.13.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory Landscape
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory Landscape
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory Landscape
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory Landscape
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory Landscape
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory Landscape
      • 8.5.4.4. Reimbursement Scenario
      • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory Landscape
      • 8.5.5.4. Reimbursement Scenario
      • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory Landscape
      • 8.5.6.4. Reimbursement Scenario
      • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory Landscape
      • 8.5.7.4. Reimbursement Scenario
      • 8.5.7.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory Landscape
      • 8.5.8.4. Reimbursement Scenario
      • 8.5.8.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Regulatory Landscape
      • 8.5.9.4. Reimbursement Scenario
      • 8.5.9.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory Landscape
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory Landscape
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory Landscape
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory Landscape
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory Landscape
      • 8.6.6.4. Reimbursement Scenario
      • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory Landscape
      • 8.6.7.4. Reimbursement Scenario
      • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory Landscape
      • 8.7.2.4. Reimbursement Scenario
      • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory Landscape
      • 8.7.3.4. Reimbursement Scenario
      • 8.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory Landscape
      • 8.8.2.4. Reimbursement Scenario
      • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory Landscape
      • 8.8.3.4. Reimbursement Scenario
      • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory Landscape
      • 8.8.4.4. Reimbursement Scenario
      • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Regulatory Landscape
      • 8.8.5.4. Reimbursement Scenario
      • 8.8.5.5. Israel market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. Parexel International (MA) Corporation.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. ICON plc
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Laboratory Corporation of America Holdings
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Thermo Fisher Scientific Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Medpace
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. IQVIA
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. CTI Clinical Trial & Consulting
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. WuXi AppTec
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Veeda Clinical Research
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5 Global Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 6 Global Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 7 Global Pharmaceutical CRO, by region, 2018 - 2030 (USD Million)
  • Table 8 North America Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 10 North America Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 11 North America Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 12 U.S. Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 15 Canada Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 18 Canada Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 19 Mexico Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 21 Mexico Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 22 Mexico Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 23 Europe Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 25 Europe Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 26 Europe Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 27 Germany Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 29 Germany Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 30 Germany Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 31 UK Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 32 UK Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 33 UK Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 34 UK Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 35 France Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 36 France Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 37 France Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 38 France Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 39 Italy Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 40 Italy Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 41 Italy Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 42 Italy Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 43 Spain Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 44 Spain Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 45 Spain Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 46 Spain Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 47 Denmark Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 48 Denmark Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 49 Denmark Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 50 Denmark Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 51 Norway Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 52 Norway Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 53 Norway Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 54 Norway Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 55 Sweden Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 56 Sweden Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 58 Sweden Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 64 China Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 65 China Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 66 China Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 67 China Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 68 Japan Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 69 Japan Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 70 Japan Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 71 Japan Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 72 India Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 73 India Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 74 India Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 75 India Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 76 South Korea Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 77 South Korea Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 78 South Korea Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 79 South Korea Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 80 Australia Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 81 Australia Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 82 Australia Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 83 Australia Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 84 Thailand Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 85 Thailand Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 86 Thailand Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 87 Thailand Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 88 Latin America Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 90 Latin America Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 91 Latin America Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 92 Latin America Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 93 Brazil Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 94 Brazil Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95 Brazil Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 96 Brazil Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 97 Argentina Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 98 Argentina Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 99 Argentina Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 100 Argentina Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 106 South Africa Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 107 South Africa Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 108 South Africa Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 109 South Africa Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 114 UAE Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 115 UAE Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 116 UAE Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 117 UAE Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmaceutical CRO Market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Pharmaceutical CRO Market: Type outlook key takeaways
  • Fig. 20 Pharmaceutical CRO Market: Type movement analysis
  • Fig. 21 Drug Discovery estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Target Validation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Lead Identification market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Lead Optimization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pre-Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Phase I Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Phase II Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Phase III Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Phase IV Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Pharmaceutical CRO Market: Molecule Type outlook key takeaways
  • Fig. 32 Pharmaceutical CRO Market: Molecule Type movement analysis
  • Fig. 33 Small Molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Large Molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Pharmaceutical CRO Market: Services outlook key takeaways
  • Fig. 36 Pharmaceutical CRO Market: Services movement analysis
  • Fig. 37 Project Management/Clinical Supply Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Data Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Regulatory/Medical Affairs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Medical Writing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Clinical Monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Quality Management/ Assurance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Bio-statistics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Investigator Payments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Laboratory market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Patient And Site Recruitment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Technology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical CRO Market: Therapeutic Areas outlook key takeaways
  • Fig. 50 Pharmaceutical CRO Market: Therapeutic Areas movement analysis
  • Fig. 51 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 CNS Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Infectious Diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Immunological Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Cardiovascular Disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Respiratory Diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Ophthalmology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Pain Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Regional marketplace outlook, 2023 & 2030 (USD Million)
  • Fig. 62 Regional marketplace: Key takeaways
  • Fig. 63 North America Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 U.S. Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Canada Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Mexico Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Europe Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 UK Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Germany Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 France Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Spain Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Italy Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Denmark Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Norway Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Sweden Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Asia Pacific Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Japan Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 China Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 India Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Australia Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 South Korea Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Thailand Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Latin America Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Brazil Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Argentina Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 MEA Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 South Africa Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Saudi Arabia Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 UAE Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Kuwait Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Market participant categorization
  • Fig. 116 Pharmaceutical CRO Market position analysis, 2023
  • Fig. 117 Strategic framework